FDA approves $2.8 million gene therapy Zynteglo - Axios
8/18/2022 12:00:00 AM2 years 8 months ago
by Tina Reed
by Tina Reed
Zynteglo is a gene therapy from Bluebird Bio that treats patients with the blood disorder beta-thalassemia.
The FDA on Wednesday approved Zynteglo, a gene therapy from Bluebird Bio that treats patients with the blood disorder beta-thalassemia. Why it matters: The one-time treatment which helps patients w… [+958 chars]
full article...